Sirvi Autor "Shahpazir, Ana" järgi

Nüüd näidatakse 1 - 2 2

listelement.badge.access-status Embargo ,
Activity of macrolides against uropathogenic Escherichia coli
(Tartu Ülikool, 2023) Shahpazir, Ana; Kaldalu, Niilo, juhendaja
Azithromycin is a macrolide antibiotic extensively used to treat several infections attributa- ble to Gram-positive bacteria. Exceptionally, azithromycin has proven to be effective in clin- ical treatment of widespread chronic infections caused by Gram-negative bacterium, Salmo- nella. While the underlying mechanisms of azithromycin’s activity against this Gram-nega- tive bacterium remain enigmatic, its efficacy brings up the question of whether this macro- lide can be used in treatment of other Gram-negative bacterial infections as well. The goal of this work was to investigate the possibility of utilizing azithromycin against uropatho- genic Escherichia coli. For this purpose, we determined the minimum inhibitory concentra- tion of azithromycin in conditions resembling intracellular infection sites. Additionally, we validated the use of four macrolide bioreporters that were based on the regulatory leader peptide coding sequence of the macrolide resistance gene, ermCL.
listelement.badge.access-status Embargo ,
Development of a Novel Claudin 6-targeting CAR-T Cell Therapy
(Tartu Ülikool, 2025) Shahpazir, Ana; Mahlakõiv, Tanel, juhendaja; Teesalu, Tambet, juhendaja; Tartu Ülikool. Loodus- ja täppisteaduste valdkond; Tartu Ülikool. Tehnoloogiainstituut
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated remarkable success in B-cell malignancies but have yet to show comparable outcomes in solid tumors. A major obstacle is the scarcity of tumor-specific antigens that enable precise and effective targeting. Claudin 6 (CLDN6), an oncofetal tight junction protein, serves as a promising target due to its aberrant upregulation in several solid tumors and absence in healthy adult tissues. In this study, we identified two CLDN6-specific antibodies and leveraged them to generate two second-generation CAR-T cells. Both constructs selectively eliminated CLDN6-positive tumor cells in vitro, while exhibiting distinct profiles in terms of efficacy and specificity. These findings present a promising avenue for developing next-generation immunotherapies for CLDN6-expressing solid tumors and provide a foundation for further development of CAR-T therapy in the treatment of solid tumors.